Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease

Figure 1 Study flowchart of eligible chronic liver diseases patients with and without confirmed coronavirus disease 2019 diagnosis for analysis. CLD: Chronic liver disease; COVID-19: Coronavirus disease 2019.

Figure 2 The cumulative incidence of study outcomes among chronic liver disease patients with and without severe acute respiratory syndrome coronavirus 2 infection. A: Hepatocellular carcinoma; B: All-cause mortality; C: Adverse hepatic outcomes; D: Palliative care. HCC: Hepatocellular carcinoma; COVID-19: Coronavirus disease 2019.

Figure 3 The cumulative incidence of study outcomes in the acute phase vs post-acute phase of infection. A: Hepatocellular carcinoma; B: All-cause mortality; C: Adverse hepatic outcomes; D: Palliative care. HCC: Hepatocellular carcinoma; COVID-19: Coronavirus disease 2019.

Figure 4 Proportion of hepatocellular carcinoma treatment modality in different groups, expressed by crude incidence rate (events/10000 person-years). HCC: Hepatocellular carcinoma; COVID-19: Coronavirus disease 2019.